Cell cycle checkpoint abrogator UCN-01 inhibits DNA repair: association with attenuation of the interaction of XPA and ERCC1 nucleotide excision repair proteins - PubMed (original) (raw)

. 1999 Sep 15;59(18):4529-34.

Affiliations

PMID: 10493501

Cell cycle checkpoint abrogator UCN-01 inhibits DNA repair: association with attenuation of the interaction of XPA and ERCC1 nucleotide excision repair proteins

H Jiang et al. Cancer Res. 1999.

Abstract

UCN-01, an anticancer agent currently in Phase I clinical trials, has been found to potentiate the cytotoxicity of cisplatin (CDDP). Because mammalian cells remove CDDP-induced DNA adducts through the nucleotide excision repair (NER) pathway, we determined the effects of UCN-01 on NER by measuring its effects on the interaction of the repair factors XPA and ERCC1 and the phosphorylation/dephosphorylation of the repair proteins. The repair activity, as measured by an in vitro repair synthesis assay and an in vivo host-cell reactivation assay using A549 cells, was significantly reduced. Although expression of XPA and ERCC1 proteins was elevated in cells exposed to UCN-01, the treatment resulted in a decreased ERCC1 level in the Triton X-100-insoluble fraction of cell lysates. A pull-down assay using the MBP-XPA fusion protein showed a significant reduction in the binding of ERCC1 to XPA in nuclear extracts from UCN-01-treated cells compared with untreated cells, suggesting that UCN-01 reduced the XPA-ERCC1 interaction. Consistent with these data, lower repair incision activity was found in the cell extracts from UCN-01-treated cells. In vitro phosphorylation revealed that UCN-01 had no effect on the phosphorylation/dephosphorylation status of either XPA or ERCC1; however, UCN-01 caused dephosphorylation of an unidentified XPA-bound protein with an apparent molecular mass of 52 kDa. Taken together, these data demonstrate the NER-inhibitory action of UCN-01, which is associated with the inhibition of the XPA-ERCC1 interaction by UCN-01 and with the effect of UCN-01 on the phosphorylation/dephosphorylation of an XPA-bound, 52-kDa protein, the identity of which remains to be determined.

PubMed Disclaimer

Cited by

Targeting the DNA Damage Response for Cancer Therapy.
Wang R, Sun Y, Li C, Xue Y, Ba X. Wang R, et al. Int J Mol Sci. 2023 Nov 2;24(21):15907. doi: 10.3390/ijms242115907. Int J Mol Sci. 2023. PMID: 37958890 Free PMC article. Review.
Every protagonist has a sidekick: Structural aspects of human xeroderma pigmentosum-binding proteins in nucleotide excision repair.
Feltes BC. Feltes BC. Protein Sci. 2021 Nov;30(11):2187-2205. doi: 10.1002/pro.4173. Epub 2021 Aug 27. Protein Sci. 2021. PMID: 34420242 Free PMC article. Review.
Targeting DNA Damage Response and Repair to Enhance Therapeutic Index in Cisplatin-Based Cancer Treatment.
Kiss RC, Xia F, Acklin S. Kiss RC, et al. Int J Mol Sci. 2021 Jul 30;22(15):8199. doi: 10.3390/ijms22158199. Int J Mol Sci. 2021. PMID: 34360968 Free PMC article. Review.
Role of Nucleotide Excision Repair in Cisplatin Resistance.
Duan M, Ulibarri J, Liu KJ, Mao P. Duan M, et al. Int J Mol Sci. 2020 Dec 4;21(23):9248. doi: 10.3390/ijms21239248. Int J Mol Sci. 2020. PMID: 33291532 Free PMC article. Review.
Clinical Perspectives of ERCC1 in Bladder Cancer.
Koutsoukos K, Andrikopoulou A, Dedes N, Zagouri F, Bamias A, Dimopoulos MA. Koutsoukos K, et al. Int J Mol Sci. 2020 Nov 22;21(22):8829. doi: 10.3390/ijms21228829. Int J Mol Sci. 2020. PMID: 33266377 Free PMC article. Review.

Cell cycle checkpoint abrogator UCN-01 inhibits DNA repair: association with attenuation of the interaction of XPA and ERCC1 nucleotide excision repair proteins - PubMed (original) (raw)